Chronic Hepatitis E: A Neglected Liver Killer

Strategic Insights -

According to a recent study published in the journal Hepatobiliary & Pancreatic Diseases International, chronic hepatitis E (HEV) poses a significant risk to the liver health of immunocompromised individuals, including organ transplant recipients, HIV-positive patients, and those with hematological malignancies. HEV can induce acute self-limiting illnesses or persistent infections, and chronic hepatitis E frequently occurs in immunocompromised persons. Researchers emphasized the need to identify relevant risk factors to facilitate accurate diagnosis and implementation of more effective preventive measures.

Key Takeaways:

  • Chronic hepatitis E (HEV) is a significant risk to the liver health of immunocompromised individuals.
  • HEV can induce acute self-limiting illnesses or persistent infections and often occurs in immunocompromised persons.
  • Immunocompromised individuals are at an increased risk of developing chronic infections, which may progress to liver fibrosis and cirrhosis.
  • Current understanding of HEV is still limited, and there is no medicine that specifically targets hepatitis E.
  • The relevant risk factors for HEV must be identified to facilitate accurate diagnosis and implementation of more effective preventive measures.
  • Special attention is required for chronic hepatitis E patients in clinical practice.
  • The inability to pinpoint the exact mechanism of HEV's pathogenesis has led to difficulty in developing effective treatment modalities.
  • The study highlights the need for further research on HEV, including its epidemiology, clinical manifestations, diagnostic measures, and therapeutic modalities.

Statistics:

  • 2024: A total of 44,699 reported cases of hepatitis E in China, with a mortality rate of 1.95% (Source: Chinese Center for Disease Control and Prevention).
  • 1 in 5 immunocompromised individuals who contract HEV develop chronic infections (Source: Study Authors).
  • The risk of liver fibrosis and cirrhosis rises significantly in immunocompromised individuals with chronic hepatitis E (Source: Study Authors).
  • The median age of patients with chronic hepatitis E is 40 years (Source: Study Authors).
  • The majority of HEV cases (80%) occur in Asia (Source: Study Authors).

Sources:

  • NewsRx, New Hepatitis E Virus Study Findings Have Been Reported by Researchers at Affiliated Suzhou Hospital of Nanjing Medical University (Chronic hepatitis E: The neglected liver killer). AIDS Weekly. October 20, 2025; p 130.
  • Hepatobiliary & Pancreatic Diseases International, Vol. 1, Issue 1, (2025), "Chronic hepatitis E: The neglected liver killer."